Starpharma has been granted a patent for dendrimers with five generations of lysine building units, cabazitazel terminal groups, and PEG groups. The patent covers pharmaceutical compositions for cancer therapy. The method involves administering the dendrimers to treat cancer effectively. GlobalData’s report on Starpharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Starpharma, was a key innovation area identified from patents. Starpharma's grant share as of May 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Cancer treatment using dendrimers with specific chemical structure
A recently granted patent (Publication Number: US11970583B2) discloses a method for treating cancer by administering a dendrimer to a subject in need. The dendrimer includes a core unit and is administered in a therapeutically effective amount ranging from 10 to 100 mg/m2 body surface area. The method specifies the treatment of various cancers such as pancreatic, prostate, breast, and ovarian cancer, including metastatic castration-resistant prostate cancer (mCRPC).
Furthermore, the method involves administering the dendrimer either as an infusion over a time period of up to 30 minutes or as a bolus over a time period of up to 5 minutes. The patent claims that the administration of the dendrimer results in enhanced clinical efficacy compared to the direct administration of an equivalent dose of free cabazitaxel. Additionally, the method aims to reduce side effects such as neutropenia, lymphopenia, anemia, and thrombocytopenia in comparison to traditional administration methods. The dendrimer composition also provides a longer plasma concentration of cabazitaxel, with specific parameters for maximal concentration and total cabazitaxel levels. The patent outlines the structure of the dendrimer, including the number of surface units and terminal groups, as well as the percentage of cabazitaxel residues within the dendrimer. The in vitro half-life for cabazitaxel release from the dendrimer is also specified in the patent.
To know more about GlobalData’s detailed insights on Starpharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
